AAO

Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation

Retrieved on: 
понедельник, марта 25, 2024
OSA, Growth, Otorhinolaryngology, Partnership, Patient, Mont-Saint-Guibert, Insurance, Euronext, AAO, Obstructive sleep apnea, CMS, Corporation, Pharmaceutical industry

Nyxoah is the first medical device company to partner with the AAO-HNSF at this level.

Key Points: 
  • Nyxoah is the first medical device company to partner with the AAO-HNSF at this level.
  • The AAO-HNSF is committed to identifying and combating harmful coverage policies that threaten access to quality otolaryngology-head and neck services.
  • The Academy’s Advocacy team, in collaboration with its dedicated members and strategic industry partners like Nyxoah, actively engage with payers to achieve this goal.
  • “Nyxoah and the AAO-HNSF share the common goal of putting patients first and making sure they have access to HGNS therapy.

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Retrieved on: 
понедельник, марта 18, 2024
Research, Adverum Biotechnologies, Vasculitis, Three Months, Macula, Chorioretinitis, Inflammation, Patient, Episcleritis, American Academy, Anti-VEGF, LUNA, Intraocular pressure, Investment, Clinical trial, Injection, Safety, Drug development, Paratriathlon, AMD, AAO, OPTIC, Retinitis, CST, Vascular occlusion, Annual general meeting, VEGF, Pharmaceutical industry

REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023. The company also provided recent pipeline highlights and corporate updates.

Key Points: 
  • The company also provided recent pipeline highlights and corporate updates.
  • 85% and 68% of patients at the 2E11 and 6E10 doses, respectively, received no supplemental injections through 26 weeks.
  • Stock-based compensation expense included in research and development expenses was $1.0 million for the fourth quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.1 million for the fourth quarter of 2023.

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
вторник, марта 12, 2024
Patient, G&A, BioCryst Pharmaceuticals, Eye, Drug delivery, Clinical trial, AAO, Extension, Webcast, Pharming, CPT, Safety, Disease, SPA, American Academy of Ophthalmology, Compass, Insurance, Diabetic retinopathy, Conference call, Aura, AMD, TKI, CLS, FDA, Administration, Conference, SCS, DME, American Academy, OASIS, Injection, Research and development, Axitinib, Pharmaceutical industry

ALPHARETTA, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $6.3 million, compared to $5.0 million for the fourth quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $2.9 million, compared to $3.2 million for the fourth quarter of 2022.
  • Other Expense: Non-cash interest expense for the fourth quarter of 2023 was $2.3 million, compared to $2.0 million for the fourth quarter of 2022.

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
среда, марта 27, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, NMIBC, Research, Melanoma, Growth, Disease, SPA, Incidence, Paratriathlon, Inflammation, Patient, Necrosis, Travel, Light, Aes, American Academy, Cancer, Șaeș, Bladder cancer, Radiation, Eye, Doctor of Philosophy, MIBC, Visual acuity, Neoplasm, ILS, Aura, Safety, Recurrence, AAO, Annual general meeting, Food, Pharmaceutical industry

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.
  • The primary endpoint is time to tumor progression when the last patient completes 15 months of follow up.
  • As of December 31, 2023, Aura had cash and cash equivalents and marketable securities totaling $226.2 million.
  • General and administrative expenses include $1.2 million and $1.1 million of stock-based compensation for the three months ended December 31, 2023 and 2022, respectively.

Prevent Blindness Provides Free Resources as Part of April's Women's Eye Health and Safety Month to Educate Women on Necessary Steps to Help Save Sight

Retrieved on: 
среда, марта 27, 2024
Orbis, IOP, Pigment, Glaucoma, Le Bonheur Children's Hospital, Social media, Pressure, Visual impairment, Contact, Paratriathlon, Intraocular pressure, AAO, Policy, Orbis International, Hormone, Diabetes, Risk, Mental health, Delta Gamma, NIH, Eyelid, Prevalence, Eye, Associate, Safety, Cataract, Menopause, University, Pregnancy, Hospital, Melasma, Public health, Lactation, Puberty, American Academy, Lens, Telecanthus, Eye disease, Graves' ophthalmopathy, Bangladesh Technical Education Board, Dry eye syndrome, Pediatrics, Birth control

CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month. According to Orbis International, globally there are 112 million more women than men living with vision loss, including blindness. Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.

Key Points: 
  • CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month.
  • Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.
  • Women have a higher prevalence of age-related macular degeneration, cataract, dry eye, glaucoma, refractive error and thyroid eye disease.
  • For more information on women's eye health topics, including fact sheets on eye diseases and eye safety, please visit PreventBlindness.org.

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
вторник, февраля 27, 2024
PEGASUS, Quarter, EMA, Committee, ALS, APLS, Recurrence, AAO, ASH, Note, Physician, FDA, Marketing, Data, Treasury, Safety, CAD, Society, VALIANT, Cold agglutinin disease, CHMP, European Medicines Agency, Administration, Patient, Public expenditure, Webcast, GALE, PRINCE, PNH, ASN, Research, Travel, American Academy, Pharmaceutical industry

Cost of sales was $19.9 million for the fourth quarter of 2023, compared to $2.9 million for the fourth quarter of 2022, respectively.

Key Points: 
  • Cost of sales was $19.9 million for the fourth quarter of 2023, compared to $2.9 million for the fourth quarter of 2022, respectively.
  • R&D expenses were $69.3 million for the fourth quarter of 2023, compared to $99.4 million for the fourth quarter of 2023.
  • G&A expenses were $141.7 million for the fourth quarter of 2023, compared to $84.4 million for the fourth quarter of 2022.
  • Apellis will host a conference call and webcast to discuss its fourth quarter and year end 2023 financial results and business highlights today, February 27, 2024, at 8:30 a.m.

The Inner Circle Acknowledges, Joshua Cohen as a Top Pinnacle Life Member

Retrieved on: 
четверг, февраля 22, 2024
Philosophy, Eye, Inner circle, AAO, Multimedia, ACRS, Laser, Harvard University, BOCA, University, Mentorship, Patient, Family, Physician, Glaucoma

BOCA RATON, Fla., Feb. 22, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Joshua Cohen is acknowledged as a Top Pinnacle Life Member for his contributions to the field of Ophthalmology.

Key Points: 
  • BOCA RATON, Fla., Feb. 22, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Joshua Cohen is acknowledged as a Top Pinnacle Life Member for his contributions to the field of Ophthalmology.
  • Dr. Cohen pursued his prestigious education at Harvard University where he earned a Bachelor of Science degree.
  • He then attended the University of Gainesville where he received a Medical Doctor degree and completed residency at the University of Virginia.
  • Dr. Cohen is an expert in Lasik surgery, advanced cataract surgery, and glaucoma.

3DMakerpro Medical Debuts New Products at AEEDC Dubai 2024 Conference

Retrieved on: 
четверг, февраля 8, 2024
IDEX, Congress, AAO, 3D, Exhibition, Digital, Medicine, Conference

DUBAI, UAE, Feb. 8, 2024 /PRNewswire/ -- 3DMakerpro Medical, a sub-brand from the 3D scanning technology pioneer 3DMakerpro, has unveiled four new products at the AEEDC Dubai 2024 Conference, the world's largest annual scientific dental conference and exhibition, held from February 6-8, 2024.

Key Points: 
  • DUBAI, UAE, Feb. 8, 2024 /PRNewswire/ -- 3DMakerpro Medical, a sub-brand from the 3D scanning technology pioneer 3DMakerpro, has unveiled four new products at the AEEDC Dubai 2024 Conference, the world's largest annual scientific dental conference and exhibition, held from February 6-8, 2024.
  • 3DMakerpro Medical has an ambitious exhibition schedule for 2024, including:
    EXPODENTAL 2024: The benchmark trade fair for the international dental sector, taking place in Madrid from March 14-16, 2024.
  • IDEM Singapore 2024: The leading dental exhibition and conference for the Asia Pacific, happening from April 19-21, 2024, in Singapore.
  • Vietnam International Dental Exhibition & Congress (VIDEC 2024): the most important dental event in Vietnam, taking place in Hanoi from Aug 21-23, 2024.

3DMakerpro Medical Debuts New Products at AEEDC Dubai 2024 Conference

Retrieved on: 
четверг, февраля 8, 2024
IDEX, Congress, AAO, 3D, Exhibition, Digital, Medicine, Conference

DUBAI, UAE, Feb. 8, 2024 /PRNewswire/ -- 3DMakerpro Medical, a sub-brand from the 3D scanning technology pioneer 3DMakerpro, has unveiled four new products at the AEEDC Dubai 2024 Conference, the world's largest annual scientific dental conference and exhibition, held from February 6-8, 2024.

Key Points: 
  • DUBAI, UAE, Feb. 8, 2024 /PRNewswire/ -- 3DMakerpro Medical, a sub-brand from the 3D scanning technology pioneer 3DMakerpro, has unveiled four new products at the AEEDC Dubai 2024 Conference, the world's largest annual scientific dental conference and exhibition, held from February 6-8, 2024.
  • 3DMakerpro Medical has an ambitious exhibition schedule for 2024, including:
    EXPODENTAL 2024: The benchmark trade fair for the international dental sector, taking place in Madrid from March 14-16, 2024.
  • IDEM Singapore 2024: The leading dental exhibition and conference for the Asia Pacific, happening from April 19-21, 2024, in Singapore.
  • Vietnam International Dental Exhibition & Congress (VIDEC 2024): the most important dental event in Vietnam, taking place in Hanoi from Aug 21-23, 2024.

Orthodontic Arts Announces Practice Expansion & Partnership with Dr. Chris Hunt

Retrieved on: 
понедельник, февраля 5, 2024
Partnership, Multimedia, Growth, University of Oklahoma, Birdwell, Oklahoma State University–Stillwater, Research, Orthodontics, AAO, Patient, Saint Louis University, Brace, Christian University, University, Dentistry

OKLAHOMA CITY, Feb. 5, 2024 /PRNewswire/ -- Orthodontic Arts, a leading orthodontic practice in Midtown OKC, announced today that founder, Dr. David Birdwell, and partner Dr. Brian Wilson, have expanded their thriving practice with a partnership with Dr. Chris Hunt.

Key Points: 
  • OKLAHOMA CITY, Feb. 5, 2024 /PRNewswire/ -- Orthodontic Arts, a leading orthodontic practice in Midtown OKC, announced today that founder, Dr. David Birdwell, and partner Dr. Brian Wilson, have expanded their thriving practice with a partnership with Dr. Chris Hunt.
  • "It has been a privilege to work alongside Dr. David Birdwell at Orthodontic Arts for these past five years.
  • Dr. Chris Hunt is a native of Oklahoma, attended Oklahoma Christian University for his undergraduate degree.
  • "I am incredibly thankful to have the opportunity to join Orthodontic Arts, which many consider one of the best orthodontic practices in Oklahoma.